Orna Therapeutics, Inc. Overview
Pro stress-test →Orna Therapeutics is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell therapies that can treat underlying disease. On February 9, 2026, Orna entered into a definitive agreement for Eli Lilly to acquire the company. Orna shareholders could receive up to $2.4 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain clinical development milestones.
Strategic Profile
Pro stress-test →Orna's lead program is ORN-252, a clinical trial-ready, CD19 targeting in vivo Chimeric Antigen Receptor T-cell (CAR-T) therapy designed to treat B cell-driven autoimmune diseases. Experiments to date suggest that Orna's circular RNA platform may deliver more durable expression of therapeutic proteins and therefore unlock treatments that are not feasible with current RNA or cell therapy platforms. The acquisition represents Eli Lilly's strategic investment in novel in vivo cell engineering technology to expand its immunotherapy portfolio.
Competitive Landscape
Pro stress-test →Skyhawk Therapeutics, Sana Biotechnology, GeneCentric, and Jubilant Therapeutics are competitors of Orna Therapeutics. Orna's competitive moat stems from its proprietary circular RNA platform with superior formulation properties and durability compared to linear mRNA competitors. The company operates in the emerging in vivo CAR-T cell therapy space where ex vivo approaches dominate but carry higher complexity and cost barriers.
Industry Context
Orna Therapeutics, Inc. operates in In vivo cell therapy development.
Key facts
Founded: 2019 · Headquarters: Cambridge, US · Employees: 175 · Revenue: N/A · Market cap: N/A (Acquisition pending)